By admin 
Shanghai-based Excalipoint Therapeutics has announced the successful closure of a substantial financing round totaling $68.7 million, earmarking these funds to accelerate the development of its pioneering portfolio of trispecific antibody-based T-cell engagers. This significant capital injection, comprising a $41 million seed round completed in late 2025 and a $27.7 million extension financing in early 2026, positions Excalipoint at the forefront of a new wave of immunotherapies designed to overcome the persistent challenges associated with treating solid tumors and mitigating the severe side effects often seen with earlier-generation treatments. The funding round, backed by a consortium of prominent investors including HSG (formerly Sequoia Capital’s Chinese division), Lilly Asia Ventures, and Eisai’s venture arm, underscores a burgeoning confidence in China’s innovative biopharmaceutical sector and in Excalipoint’s unique technological approach.
The Evolving Landscape of T-Cell Engagers and Unmet Needs in Oncology
T-cell engagers represent a groundbreaking class of immunotherapies that harness the body’s own immune system to combat disease. These engineered antibodies function by creating a molecular bridge between T cells – the body’s potent immune fighters – and diseased cells, such as cancer cells. By binding to specific targets on both cell types, they effectively direct T cells to identify and destroy their pathological counterparts, initiating a targeted immune attack. The appeal of T-cell engagers extends beyond their direct therapeutic mechanism; they are increasingly viewed by drugmakers as potentially more convenient and accessible alternatives to complex cell therapies like CAR T-cells, which typically require specialized administration centers and intricate manufacturing processes.
The therapeutic promise of T-cell engagers has already been realized in several key areas. To date, U.S. regulatory bodies have approved ten T-cell engager therapies for various malignancies, demonstrating their efficacy and establishing their place in modern oncology. However, the vast majority of these approvals have been for hematological (blood) cancers, where the malignant cells are more readily accessible to circulating antibodies. The journey to effectively treat solid tumors with T-cell engagers has proven significantly more arduous.
Solid tumors present a formidable array of challenges. Their complex and often immunosuppressive microenvironments, characterized by dense extracellular matrix, heterogeneous cell populations, and various immune evasion mechanisms, make it difficult for T-cell engagers to penetrate, bind effectively, and sustain an immune response. Furthermore, a major hurdle has been the management of dose-limiting toxicities, most notably cytokine release syndrome (CRS). CRS is a severe systemic inflammatory response caused by the rapid and widespread activation of immune cells, leading to symptoms ranging from fever and fatigue to multi-organ failure. The risk of CRS often necessitates lower dosing, which can compromise therapeutic efficacy. Tumors also possess the insidious ability to develop resistance mechanisms, further limiting the long-term impact of these treatments. These challenges highlight a critical unmet medical need for more precise, potent, and safer T-cell engager therapies.
Excalipoint’s Innovative Strategy: Trispecificity and Masking Technology
Excalipoint Therapeutics is directly confronting these challenges with a novel strategy centered on developing a portfolio of trispecific (three-target) T-cell engagers, augmented by proprietary "masking" technology. This innovative approach aims to significantly enhance therapeutic index – improving efficacy while reducing toxicity – particularly in the notoriously difficult-to-treat solid tumor landscape.
Traditional T-cell engagers are typically bispecific, meaning they bind to two different targets: one on the T cell (commonly CD3) and one on the tumor cell. Excalipoint’s CEO, Lei Fang, articulates that the addition of a third target offers several critical advantages. This trispecific design is hypothesized to improve the specificity and avidity of the engager, allowing for more precise targeting of cancer cells while minimizing off-target interactions with healthy tissues. Crucially, a third binding arm can be engineered to engage additional tumor-associated antigens or co-stimulatory molecules on immune cells, potentially boosting the T cell’s activation and cytotoxic function, particularly against "cold" tumors. These "cold" tumors are characterized by a lack of immune cell infiltration and low immunogenicity, making them resistant to many conventional immunotherapies. By engaging multiple targets, Excalipoint believes its trispecific antibodies can better "awaken" the immune system to recognize and attack these elusive malignancies.
Complementing its trispecific architecture, Excalipoint is integrating a sophisticated "masking" technology into its drug candidates. This ingenious mechanism is designed to keep the T-cell engager in an inactive or "masked" state while circulating throughout the body, only becoming fully activated when it encounters the specific microenvironment of a tumor. This spatial and contextual activation is intended to dramatically reduce systemic toxicity, especially the dreaded cytokine release syndrome. By selectively activating the immune response at the tumor site, the masking technology aims to spare healthy tissues from immune-mediated damage, allowing for potentially higher, more effective dosing while maintaining a superior safety profile. This dual strategy of enhanced targeting and localized activation represents a significant leap forward in T-cell engager design.
Key Programs: EXP011 and EXP012
Excalipoint’s lead program, EXP011, exemplifies this innovative approach. It is designed to target the cancer protein DLL3 (Delta-like ligand 3), a neuroendocrine tumor marker, along with two distinct immune cell targets. DLL3 is often overexpressed in small cell lung cancer (SCLC) and other neuroendocrine tumors, making it a promising target for this difficult-to-treat patient population. By engaging DLL3 and simultaneously activating T cells via two immune checkpoints, EXP011 aims to orchestrate a powerful and specific anti-tumor response.
A second critical "trispecific" antibody, EXP012, is also under development. This program targets the same two immune cell targets as EXP011, but its tumor-specific arm is directed against CDH17 (Cadherin-17). CDH17 is a cell adhesion molecule found to be highly overexpressed in various gastrointestinal cancers, including gastric, colorectal, and pancreatic cancers. Given the high incidence and often poor prognosis of these malignancies, EXP012 holds significant potential to address a substantial unmet medical need in oncology.
Both EXP011 and EXP012 were licensed by Excalipoint from Lepu Biopharma, another prominent Chinese drug developer. This strategic licensing agreement involved an upfront payment of $10 million, signaling the value placed on these foundational assets. Notably, Excalipoint’s CEO, Lei Fang, previously served as a vice president at Lepu Biopharma, suggesting a continuity of vision and a deep understanding of the scientific and commercial potential of these programs. This connection underscores a growing trend in China where seasoned biopharma executives leverage their experience and networks to launch new, highly focused ventures, often building upon intellectual property from their previous roles.
A Significant Vote of Confidence from Investors
The substantial $68.7 million financing package is a powerful testament to the investor community’s confidence in Excalipoint’s scientific platform, leadership team, and market potential. The seed round of $41 million, completed in late 2025, was reported by Excalipoint to be one of the largest ever for a Chinese biotech startup. This accomplishment not only highlights the scale of ambition but also the increasing maturity and attractiveness of China’s venture capital ecosystem for innovative life sciences companies. The subsequent $27.7 million extension financing further solidified this financial backing.
The investor syndicate is particularly noteworthy, featuring globally recognized names. HSG, the former Chinese division of Sequoia Capital, brings deep market insight and a proven track record in nurturing successful startups. Lilly Asia Ventures, the venture capital arm of pharmaceutical giant Eli Lilly, provides strategic validation and potential future partnership avenues, given Lilly’s extensive global presence and expertise in oncology. Similarly, Eisai’s venture arm represents the investment interests of a leading Japanese pharmaceutical company with a strong focus on oncology and neurology, further diversifying the expertise and connections within Excalipoint’s investor base. The involvement of such high-caliber investors signals not only financial strength but also strategic alignment, mentorship, and access to crucial industry networks, which are invaluable for an early-stage biotech company navigating complex drug development pathways.
China’s Ascendant Role in Global Biopharmaceutical Innovation
Excalipoint’s success story is emblematic of China’s rapid ascent as a formidable force in the global biopharmaceutical landscape. Over the past decade, China has transitioned from primarily being a manufacturing hub to a vibrant center for cutting-edge scientific research and drug innovation. This transformation is driven by several factors: substantial government investment in R&D, a burgeoning pool of highly skilled scientific talent, increasingly sophisticated regulatory frameworks, and a robust venture capital environment eager to back innovative life science ventures.
The trend of "multifunctional drugs from China" has been particularly pronounced. BioPharma Dive data indicates that since the beginning of 2025, at least 22 significant licensing pacts have been struck between U.S. or European companies and their China-based counterparts. These deals, often involving substantial upfront payments and milestone opportunities, demonstrate a growing recognition of the scientific prowess emanating from Chinese biotechs. Recent examples include licensing agreements involving well-funded startups such as Ouro Medicines and Ollin Biosciences, which are also developing innovative therapies, including T-cell engagers and other complex biologics. This influx of cross-border collaborations signifies a global integration of R&D efforts and a strategic acknowledgment of China’s capabilities in developing next-generation therapeutic modalities.
Excalipoint’s leadership explicitly articulates global ambitions. Jielun Zhu, the company’s chief financial officer, stated, "In the future, doing partnership deals with multinational companies or with pharmaceutical companies outside of China, is one important strategy for us." This statement underscores a clear intent to not only develop innovative therapies within China but also to seek broader global validation and market access through strategic alliances. Such partnerships are crucial for expanding clinical development, navigating diverse regulatory landscapes, and ultimately bringing novel treatments to patients worldwide.
Operational Hub and Strategic Location
Excalipoint Therapeutics is strategically headquartered within the prestigious Roche Accelerator building in Shanghai. This location offers more than just office space; it provides access to state-of-the-art laboratory facilities, a collaborative ecosystem, and proximity to other innovative biotech and pharmaceutical entities. The Roche Accelerator, an initiative by one of the world’s leading pharmaceutical companies, is designed to foster innovation by supporting promising startups with resources, mentorship, and a conducive environment for scientific discovery and development. Being situated within such an esteemed hub lends credibility to Excalipoint and facilitates potential collaborations and knowledge exchange.
Shanghai itself has emerged as a powerhouse in China’s biopharmaceutical industry. The city boasts a robust infrastructure for R&D, a highly educated workforce, and supportive government policies aimed at nurturing biotech innovation. This vibrant ecosystem provides Excalipoint with access to top talent, cutting-edge technology platforms, and a dynamic network of academic institutions and industry partners, all crucial ingredients for accelerated drug development.
Implications for the Future of Oncology and Beyond
The emergence of Excalipoint Therapeutics, backed by significant capital and a highly innovative scientific platform, holds profound implications for the future of oncology and potentially other therapeutic areas where immune modulation is key. If Excalipoint’s trispecific T-cell engagers with masking technology prove successful in clinical trials, they could redefine the treatment paradigm for solid tumors, offering safer and more effective options for patients who currently have limited choices. The ability to circumvent issues like cytokine release syndrome and tumor resistance could unlock the full therapeutic potential of T-cell engagers in indications previously deemed intractable.
The success of Excalipoint will also further solidify China’s position as a global leader in biopharmaceutical innovation, attracting more investment and talent, and fostering a virtuous cycle of scientific discovery. It will intensify competition within the T-cell engager space, pushing both established pharmaceutical companies and other emerging biotechs to innovate further, potentially accelerating the development of even more sophisticated immunotherapies.
Looking ahead, Excalipoint’s immediate next steps will likely involve advancing its lead programs, EXP011 and EXP012, through preclinical development towards investigational new drug (IND) applications, paving the way for human clinical trials. While significant challenges lie ahead in clinical validation, regulatory hurdles, and market access, the substantial financing and the compelling scientific rationale behind Excalipoint’s approach suggest that it is well-positioned to make a lasting impact on global health. The company’s strategic focus on overcoming current limitations in T-cell engager therapy, combined with its strong financial backing and global aspirations, marks it as a key player to watch in the evolving landscape of precision medicine.